THE NUMBERS

~40%

Lean Mass Loss (Unguided)

Without resistance training, up to 40% of weight lost on GLP-1s can come from lean tissue, not just fat.

~3%

Muscle Lost (With Protocol)

In a 200-person study, participants guided on resistance training and protein lost only 3% muscle despite 13% total weight loss.

60%

Of Trainers Report Muscle Loss as #1 Client Concern

NASM survey of nearly 500 fitness pros: muscle wasting is now the primary issue raised in GLP-1 client sessions.

65%

Discontinue Within 12 Months

Most users quit within a year. When they do, weight rebounds fast and the lost muscle is slow to return.

46%

Trainers See Strength Training as Top Opportunity

NASM data shows longevity and strength coaching are now viewed as the industry's biggest growth window.

800K+

Genetic Records Analyzed

University of Hong Kong study using Mendelian randomization on 800,000 individuals confirmed GLP-1s reduce more fat than lean mass overall, but muscle loss is not negligible.

02

THE SCIENCE

// WHAT GLP-1 MEDICATIONS DO

GLP-1 receptor agonists were originally developed to treat type 2 diabetes. They mimic the glucagon-like peptide-1 hormone, which limits blood sugar spikes after eating and slows gastrointestinal motility.

The weight loss effect comes primarily from dramatically reduced appetite. Users eat far less, and the caloric deficit compounds over months. Drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have produced 15-25% body weight loss in 12-24 month trials.

// THE BODY COMPOSITION QUESTION

Any rapid weight loss creates a body composition question: how much of that lost weight is fat, and how much is muscle? The answer with GLP-1s depends almost entirely on what the user is doing alongside the medication.

Unguided users can lose up to 40% of total weight from lean body mass. With proper resistance training and protein protocols, that figure drops to roughly 3% in clinical study conditions. That 37-point spread is the entire argument for strength coaching.

Important nuance: A 2025 mouse-model study and analyses from UC Davis found that not all "lean mass" loss on GLP-1s is skeletal muscle. Much comes from other tissue, including the liver. Skeletal muscle loss is closer to 20% of lean mass loss, not 40%. Still significant. Still not acceptable without countermeasures.

// HOW MUSCLE GETS LOST

GLP-1 medications suppress appetite aggressively. Users consume far fewer calories, and critically, far less protein. A 2025 NIH-published study confirmed that GLP-1 users show systematically suboptimal protein intake relative to the 1.2-2.0g/kg/day needed to protect lean mass during hypocaloric diets.

Without adequate protein and mechanical loading, the body treats muscle as a caloric reservoir. In a large deficit, it cannibalizes lean tissue alongside fat. Progressive overload is the signal that tells the body: this tissue is necessary. Keep it.

// WHAT THE RESEARCH CONFIRMS

A meta-analysis from the University of Hong Kong using 800,000+ genetic records confirmed GLP-1s produce more fat loss than lean loss overall, and overall body composition improves. That's the good news.

But the loss of lean mass is not negligible, and for certain populations, particularly older adults, it triggers accelerated sarcopenia. Loss of skeletal muscle impairs metabolic health, diminishes physical function, and makes weight maintenance harder if the medication is discontinued.

The metabolic penalty: Skeletal muscle is the body's primary metabolic engine. When you lose it, your basal metabolic rate drops. And it drops significantly. This is not a minor rounding error; it's a structural shift in how many calories your body needs to survive at rest.

Skeletal muscle is metabolically active tissue. A body that carries more muscle burns more calories at rest around the clock. GLP-1-induced muscle loss creates what researchers describe as a metabolic penalty: basal metabolic rate falls in proportion to lean mass lost.

The compounding problem: if a user loses significant muscle and then stops the medication, they now have a body that requires fewer calories, has regained appetite, and has lost the structural integrity to build that muscle back quickly. Harvard Science Review (February 2026) described this as the setup for "rapid, aggressive fat regain" that is harder to reverse than standard weight cycling.

This is precisely why the industry's focus has shifted from "burn calories" to "protect the chassis." The chassis, once compromised, changes the economics of every intervention that follows.

// THE DISCONTINUATION PROBLEM

Up to 65% of GLP-1 users discontinue within 12 months, driven by cost and side effects. A substantial portion reinitiate treatment. This creates cycles of drug-off, drug-on, weight-loss, weight-regain.

A University of Oxford review found that weight regain after stopping GLP-1s often begins faster than after ending traditional diet and exercise programs. The body has been physiologically reset, and not in a favorable direction.

// SARCOPENIC OBESITY

Weight cycling has been linked to lower lean mass and muscle strength, especially across multiple cycles. Sarcopenic obesity, characterized by excessive body fat alongside low skeletal muscle mass, is already prevalent in 10-20% of older adults.

Research from the University of Liverpool warns that repeated GLP-1 cessation in older adults may exacerbate this risk: each cycle potentially leaving them with more fat and less muscle than the last, accelerating age-related functional decline.

03

THE INDUSTRY SHIFT

GLP-1 medications were described by NASM as the single most disruptive force in fitness in 2025. The role of a personal trainer has been structurally redefined. The mission is no longer calorie burn. It's lean mass preservation.

BEFORE GLP-1 ERA

Fat Loss Was the Primary Objective

Coaches designed around caloric expenditure. HIIT, cardio-forward programming, caloric restriction. Success was measured in pounds lost and calories burned. Muscle was secondary to "losing the weight."

2024-2025: INDUSTRY RECKONING

The Muscle Wasting Problem Goes Mainstream

Clinical data on lean mass loss with GLP-1 medications hits mainstream awareness. NASM surveys show muscle loss is now the #1 client concern. Major fitness chains like Orangetheory and Anytime Fitness redesign programming around lean mass preservation for GLP-1 users. Noom launches "Muscle Defense" program. A "GLP-1 Certified Personal Trainer" trademark is filed.

2025-2026: NEW STANDARD OF CARE

Coaches Become Medical Collaborators

74% of fitness professionals agree that collaboration with medical providers is no longer optional. The "gym-as-clinic" model expands. In January 2026, CMS announced the BALANCE Model, creating a government-funded referral pipeline for fitness brands that qualify as "authorized lifestyle providers" for GLP-1 patients. Body comp replaces BMI as the core metric. DEXA scans become standard tools.

THE EMERGING SCIENCE LAYER

New Interventions Being Tested

Virginia Tech launched STRONG-GLP, a clinical trial specifically studying strength training response in GLP-1 users (began 2025, completing 2027). Researchers at the American Diabetes Association presented data on bimagrumab, an experimental muscle-preserving drug, in combination with semaglutide. A biosensor to track muscle breakdown in real-time via phenylalanine levels is in development. The science is accelerating fast.

04

WITH VS. WITHOUT

This is the delta that matters. What happens to your client's body composition with GLP-1 medication depends almost entirely on whether they have a proper resistance + protein protocol in place.

% OF TOTAL WEIGHT LOSS THAT IS LEAN MASS

GLP-1 + NO PROTOCOL Up to 40%

STANDARD CALORIC RESTRICTION (NO GLP-1) ~20-25%

GLP-1 + RESISTANCE TRAINING + HIGH PROTEIN ~3%

Sources: Medscape (Peralta-Reich, 200-person prospective study, April 2025); UC Davis Keith Baar commentary; University of Hong Kong meta-analysis (800K+ individuals). Figures approximate; individual results vary.

That 37-point spread between "no protocol" and "resistance + protein protocol" is not a marginal difference. It's the difference between a client who walks off the medication metabolically stronger than when they started, and one who is more fragile, more prone to rebound, and harder to help long-term.

05

THE PROTOCOL

The science is clear on what works. The implementation is where most GLP-1 users are left on their own. This is the gap coaches are built to fill.

PILLAR	PRESCRIPTION	WHY IT MATTERS
PROTEIN	Target 1g per lb of lean body mass (or 1.2-2.0g/kg bodyweight adjusted). Prioritize leucine-rich sources: lean meat, eggs, Greek yogurt.	GLP-1 suppresses appetite, which suppresses protein intake. This is the #1 reason muscle is lost. Must be proactively managed.
TRAINING	2-3x per week resistance training targeting all major muscle groups. Heavy compound movements: squat, hinge, press, row. Progressive overload required, not maintenance.	Mechanical loading is the biological signal to preserve lean tissue. Without it, the body has no reason to maintain metabolically expensive muscle under caloric restriction.
VOLUME	8-12 reps per set, 2-3 sets per exercise. Prioritize quality over quantity given reduced energy from caloric deficit. Rest 48hrs between sessions.	GLP-1 users are in a caloric deficit. Volume should be sufficient to stimulate, not so high it exceeds recovery capacity.
TRACKING	Use body composition measurements, not scale weight. DEXA scans where available. Track strength performance, movement quality, and energy levels as primary markers.	Scale weight hides what's actually happening. A client can lose 12 lbs on the scale while losing 8 lbs of muscle and only 4 of fat. That's a failure, not a win.

06

COACH LIONEL'S TAKE

// TELEPORT STRENGTH PERSPECTIVE

I've watched the fitness industry spend 30 years obsessed with the wrong number. The scale. Calories burned. Cardio minutes. The GLP-1 era is, ironically, the thing that finally forced the conversation to the right place: what is the body actually made of, and is it capable?

Here's what nobody's telling GLP-1 users at the pharmacy: the drug does not care about your muscle. It suppresses your appetite, and appetite suppression in the absence of resistance training and protein is a recipe for becoming smaller and weaker at the same time. You lose weight and you lose the engine. That's not a win. That's a setup for the rebound of your life when you stop the medication.

The stat that should scare every GLP-1 user: up to 70% stop within the first year. When they do, the body that was burning 1,800 calories at rest is now burning 1,500 because they lost the muscle tissue that drove that metabolism. The weight comes back fast. The muscle does not come back fast. That's the trap.

This is why we've always preached the iron as non-negotiable. Not for aesthetics. Not for the gym selfie. For the chassis. The physical infrastructure that makes everything else possible. GLP-1 medications are a tool. Progressive overload and high protein are the framework that makes those tools work long-term without destroying what matters most.

If you or someone you know is on these medications and not in the weight room, this is the conversation that needs to happen. The drug is handling the appetite. The coach handles the muscle. Both are required.